Лучшие больницы для «Uterus Transplant» в Хайдарабад, Индия

Absolute uterine factor infertility (AUFI) affects an estimated 1 in 500 women of reproductive age worldwide and historically represented the only form of female infertility with no medical solution — leaving adoption and gestational surrogacy (where legally available) as the sole pathways to parenthood. AUFI arises from congenital uterine absence (Mayer-Rokitansky-Küster-Hauser syndrome, affecting approximately 1 in 4,500 female births), bilateral Müllerian duct agenesis, or acquired causes including hysterectomy for postpartum haemorrhage, cervical cancer, or fibroids, as well as severe Asherman's syndrome with complete endometrial obliteration. The physiological consequence extends beyond fertility: many affected women experience profound psychological burden, grief, and identity disturbance, making uterus transplantation not merely a fertility intervention but a transformative reconstructive procedure.

• ELIGIBLE PATIENTS:
• Women of reproductive age (typically 18–40 years) with confirmed absolute uterine factor infertility (AUFI)
• Congenital uterine absence: Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome Type I or Type II (with normal ovarian function confirmed)
• Acquired uterine absence: post-hysterectomy (benign or oncologic indication, with oncologic patients requiring minimum 5-year disease-free survival certification)
• Severe Asherman's syndrome (Grade IV, complete obliteration) unresponsive to hysteroscopic lysis and estrogen priming
• +34 more

Programme Phases OVERVIEW:

Uterus transplantation is not a single operation but a structured multi-year clinical programme encompassing five distinct phases: (1) IVF and embryo banking, (2) donor selection and workup, (3) transplant surgery, (4) pregnancy achievement and obstetric management, and (5) planned uterus explantation.

PHASE 1 — IVF AND Embryo CRYOPRESERVATION:

Before any surgical listing, the recipient undergoes controlled ovarian stimulation (COS) using a GnRH antagonist protocol (e.g., Cetrotide/Ganirelix) or a long agonist downregulation protocol, followed by oocyte retrieval under transvaginal ultrasound guidance. Embryos are created via conventional IVF or Intracytoplasmic Sperm Injection (ICSI) and vitrified using the Cryotop/Kitazato vitrification system, which achieves > 90% post-thaw survival rates. A minimum of 3–5 vitrified blastocysts (Day 5/6 embryos, PGT-A tested where indicated) is recommended before transplant listing, as embryo transfer cannot occur until 6–12 months post-transplant and only during stable immunosuppression.

STEP 1 — INITIAL CONSULTATION AND GAF HEALTHCARE CASE REVIEW (Weeks 1–4, Remote): The patient submits medical records, imaging (pelvic MRI, hormonal panels), and prior reproductive history to GAF Healthcare's clinical team. A teleconsultation is arranged with the lead transplant surgeon and reproductive endocrinologist. Eligibility is assessed against ISUTx criteria. A preliminary treatment roadmap and cost estimate are provided.

STEP 2 — IVF AND EMBRYO BANKING (Months 1–3, In-Country or Home Country): Controlled ovarian stimulation and oocyte retrieval are performed — ideally at the destination centre or at the patient's home fertility clinic under a shared-care protocol. A minimum of 3–5 vitrified blastocysts are created and banked. PGT-A (preimplantation genetic testing for aneuploidy) is recommended to maximise the chance of successful embryo transfer post-transplant.

STEP 3 — DONOR EVALUATION AND WORKUP (Months 2–4, Concurrent with IVF): Living donor (or deceased donor coordination) workup is completed: HLA typing, PRA/crossmatch, vascular imaging (CTA pelvis), psychological evaluation, ethics board approval (mandatory under THOTA in India; DHA/HAAD regulations in the UAE), and ROTTO/SOTTO registration in India. This phase requires 2–3 in-person visits to the transplant centre.